Cargando…

Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors

Glioblastoma multiforme (GBM) is the most common primary brain cancer. Even with aggressive combination therapy, the median life expectancy for patients with GBM remains approximately 14 months. In order to improve the outcomes of patients with GBM, the development of newer treatments is critical. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicholas, Sarah, Mathios, Dimitris, Ruzevick, Jacob, Jackson, Christopher, Yang, Isaac, Lim, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Brain Tumor Society and The Korean Society for Neuro-Oncology 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027120/ https://www.ncbi.nlm.nih.gov/pubmed/24904882 http://dx.doi.org/10.14791/btrt.2013.1.1.2

Ejemplares similares

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
por: Jackson, Christopher, et al.
Publicado: (2011)

Current Trends in Targeted Therapies for Glioblastoma Multiforme
por: Ohka, Fumiharu, et al.
Publicado: (2012)

Current Immunotherapies for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2021)

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
por: Kim, Eileen S., et al.
Publicado: (2016)

Current data and strategy in glioblastoma multiforme
por: Iacob, G, et al.
Publicado: (2009)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

Radiation and concomitant chemotherapy for patients with glioblastoma multiforme
por: Villà, Salvador, et al.
Publicado: (2014)

STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
por: Kim, Jennifer E., et al.
Publicado: (2014)

Current and Future Novel Treatments for Glioblastoma Multiforme
por: Tyler, Betty, et al.
Publicado: (2014)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme
por: Mazurek, Marek, et al.
Publicado: (2020)

Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme
por: Mazurek, Marek, et al.
Publicado: (2020)

Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects
por: Chowdhury, Selia, et al.
Publicado: (2021)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Why is immunotherapy for glioblastoma “Lag”-ging
por: Mathios, Dimitrios, et al.
Publicado: (2019)

Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme
por: Zhang, Botao, et al.
Publicado: (2019)

Brain Cancer Stem Cells: Current Status on Glioblastoma Multiforme
por: Facchino, Sabrina, et al.
Publicado: (2011)

Current promising treatment strategy for glioblastoma multiform: A review
por: Bahadur, Sanjib, et al.
Publicado: (2019)

Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
por: Park, Jang Hyun, et al.
Publicado: (2022)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
por: Yalamarty, Satya Siva Kishan, et al.
Publicado: (2023)

Immune phenotypes predict survival in patients with glioblastoma multiforme
por: Mostafa, Haouraa, et al.
Publicado: (2016)

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
por: Pearson, Joshua R. D., et al.
Publicado: (2020)

The identification of mitochondrial DNA variants in glioblastoma multiforme
por: Yeung, Ka Yu, et al.
Publicado: (2014)

TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells
por: Scuderi, Sarah A., et al.
Publicado: (2021)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)

Glioblastoma Multiforme Survivor With Radiation-Induced Consequences: A Case Report
por: Hunt, Christina M, et al.
Publicado: (2022)

In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme
por: Kirubakaran, Palani, et al.
Publicado: (2011)

Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2018)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
por: Zhao, Hua-fu, et al.
Publicado: (2017)

Tectal plate glioblastoma multiforme
por: Nemer, Michael D., et al.
Publicado: (2011)

Bilateral cystic glioblastoma multiforme
por: Kumar, Sushil, et al.
Publicado: (2013)

Glioblastoma Multiforme Stem Cells
por: Dimov, Irena, et al.
Publicado: (2011)

Atypical Presentation of Glioblastoma Multiforme
por: Al-Janabi, Wissam, et al.
Publicado: (2018)

Nanotechnology for Treatment of Glioblastoma Multiforme
por: Michael, Justin S., et al.
Publicado: (2018)

The complement system in glioblastoma multiforme
por: Bouwens van der Vlis, T. A. M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2kc2srtg88icfkc1cge704r94h